FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor Fitzgerald
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Cantor Fitzgerald upped their FY2017 earnings per share (EPS) estimates for Aquinox Pharmaceuticals in a research report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now expects that the company will earn ($2.06) per share for the year, up from their previous forecast of ($2.36). Cantor Fitzgerald currently has a “Buy” rating and a $28.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aquinox Pharmaceuticals’ FY2018 earnings at ($2.11) EPS.
Several other equities analysts also recently commented on AQXP. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $22.50.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $10.43 on Wednesday. Aquinox Pharmaceuticals has a 52-week low of $10.23 and a 52-week high of $19.97.
Several large investors have recently bought and sold shares of AQXP. Alyeska Investment Group L.P. lifted its holdings in Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock worth $4,010,000 after acquiring an additional 5,046 shares in the last quarter. University of Notre Dame DU Lac lifted its holdings in Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after acquiring an additional 19,066 shares in the last quarter. Investment Centers of America Inc. bought a new position in Aquinox Pharmaceuticals during the third quarter worth about $175,000. Citadel Advisors LLC bought a new position in Aquinox Pharmaceuticals during the third quarter worth about $194,000. Finally, Sphera Funds Management LTD. lifted its holdings in Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after acquiring an additional 13,450 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.